Clinical trials: Current Major Depressive Disorder
- Condition Current Major Depressive Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Major Depressive Disorder
Empower: tDCS for Major Depressive Disorder at Home
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home.
- Trial name
- NCT05202119
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Flow Neuroscience AB
Depressive Disorder, Depression
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode
- Trial name
- NCT03288714
- Testing
- Synchronized Transcranial Magnetic Stimulation (sTMS)
- Where
- 14 sites in United States
- Volunteers
- 121 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment…
- Trial name
- NCT03093025
- Testing
- TS-121 10 mg, TS-121 50 mg
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-2 (NCT05550532)
- Testing
- Aticaprant
- Where
- 131 sites in United States, Argentina and 12 more
- Volunteers
- 444 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Major Depressive Disorder
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Depression
The purpose of this research study is to study closed-loop transcranial alternating current stimulation (tACS) to determine its effects on symptoms of depression in people with major depressive disorder.
- Conditions
- Depression, Major Depressive Disorder, tACS
- Trial name
- CLACS (NCT05772702)
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Electromedical Products International, Inc.